Kornimate/medical-research-clean huggingface dataset:
long follow up on patients with obstructive sleep apnea that undergo diagnosis and surgical treatment

Conditions: OSA

Summary: long follow up on patients with obstructive sleep apnea that undergo diagnosis and surgical treatment

drug induced sleep endoscopy (dise) is increasingly performed procedure, offering dynamic upper airway evaluation during artificial sleep before surgical treatment for patients with obstructed .)osa(sleep apnea * aim: to evaluate the value of dise for tailoring the proper treatment for patients with snoring and osa dise is a safe procedure, easily practicable, valid and reliable. we consider it a fundamental clinical procedure that is essential before choosing the surgical treatment. our results so far suggest that a multilevel collapse is significantly associated with higher apnea hypopnea index values. we think that the weight did not play a significant role in rdi (respiratory disturbance index) reduction. our results till now show tailored surgery based on dise may leverage sleep surgeries outcome significantly presenting 70% success rate based * on our experience we therefore want to evaluate the patients in a long follow up period

Eligibility criteria:
inclusion criteria: * fully diagnosed patients with osa. * patients who are candidates for a surgery as a treatment to their condition. exclusion criteria: * pregnancy * patients who are not osa surgery candidates. * patients with high surgical risk. * patients with hematological or oncological background.
rarecells molecular biomarkers for early detection of lung cancer

Conditions: Lung Cancer; Pulmonary Neoplasm

Summary: early diagnosis of lung cancer is a public health priority. additionally, early detection of recurrences after treatment is crucial for optimizing disease management. this study seeks to demonstrate the accuracy of the rarecells iset® circulating tumor cells dna (ctc-dna), combined with circulating tumor dna (ctdna), for the early diagnosis of lung cancer.

researching for tumor biomarkers in the blood, circulating tumor cells (ctcs), and circulating tumor dna (ctdna) can non-invasively detect signs of cancer without risk to the patient. these are ideal and risk-free methods for monitoring patients and early detection of lung cancer. this study aims to assess the sensitivity of molecular analyses performed on circulating tumor dna in the blood and on dna from circulating tumor cells, isolated using the highly sensitive iset® method. the purpose is to assess two circulating molecular biomarkers in the field of liquid biopsy in patients with lung cancer: rarecells iset® ctc-dna and ctdna. subjects eligible for inclusion in the study are individuals diagnosed with operable lung cancer who will undergo biopsy or surgical resection of the tumor. upon enrolment in the trial, participants will undergo an assessment including low-dose ct scan, isolation of ctcs by the iset® method, and separation of plasma for analysis of ctdna.

Eligibility criteria:
inclusion criteria: 1. male or female aged between 35 and 85 years 2. patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer. 3. patient capable of giving free, informed, and express consent the assessment of successful elected surgery implies, but is not limited to, the following: * exclusion of detectable extra thoracic and distant metastases * determination of the presence or absence of superior mediastinal lymph node metastases * definition of the histologic or cell type, whenever possible * evaluation of operative risk exclusion criteria: 1. patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration 2. patient treated with neoadjuvant treatment 3. pregnant women 4. patient presenting psychiatric or neurological disorders preventing them from understanding the research

Keywords: circulating tumor cells lung cancer circulating tumor dna pulmonary neoplasm
freedom solo stentless heart valve study

Conditions: Aortic Stenosis; Aortic Insufficiency

Summary: the purpose of this clinical investigation is to demonstrate the safety and effectiveness of the freedom solo heart valve.

the solo clinical investigation is a prospective, non-randomized, multicenter trial of the solo freedom heart valve implanted in patients requiring aortic valve replacement.

Eligibility criteria:
inclusion criteria: * the subject is male or female 18 years old or older. * the subject or subject's legal representative is willing to sign the informed consent. * the subject which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement. * any subject amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures. * the subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable). * subject will be available to the investigator(s) for postoperative follow-up beyond one year. exclusion criteria: * the subject has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position. * the subject requires a double or multiple valve replacement (a valve repair is not considered an exclusion criterion). * the subject has a previously implanted solo valve, within the clinical study, that requires replacement. * the subject has active endocarditis or myocarditis. * the subject is or will be participating in a concomitant research study of an investigational product. * the subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent. * the subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject. * the subject is pregnant, planning to become pregnant or lactating. * the subject has a congenital bicuspid aortic valve. * the subject is known to be noncompliant or is unlikely to complete the study. * the subject is undergoing renal dialysis for chronic renal failure or has been diagnosed with hyperparathyroidism. * the subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery. * the subject has extensive calcification of the aortic root where removal of the calcified tissue cannot be achieved. * the subject has a significantly dilated aortic root that is not surgically corrected. * the subject requires replacement of the aortic root / full root procedure.

Keywords: aortic valve replacement
covid-19 serological testing of patients with a mental disorder from the catchment area of the capital region of denmark

Conditions: Covid19; Severe Mental Disorder

Summary: the pandemic of coronavirus disease 2019 (covid-19) caused by the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) has lately caused worldwide health problems. patients suffering from a severe mental disorder are at increased risk for infectious diseases. the primary aim of the present surveillance study is to perform covid-19 serological testing on patients with a diagnosis of schizophrenia, schizoaffective disorder or a bipolar affective disorder. patients from the catchment area of the capital region of denmark will be covid-19 tested at baseline (0 months) and again at 6 and 12 months, in order to follow the spread of covid-19 among this vulnerable patient population.

patients suffering from severe mental illness could be in increased risk for a severe outcome if infected with covid-19. also, there are reports on fewer treatment activities among psychiatric patients (e.g. higher heart disease mortality), lower hospitalization rate and fewer invasive cardiac procedures among persons with schizophrenia than among the general population. this conveys a risk not only for the patient but for the spread of covid-19 in the community. at present, we expect the outcome of a covid-19 infection to be worse among the mentioned psychiatric patient population, but whether the spread of covid-19 differs from the pattern observed in the general population is unknown. this information is of pivotal interest to come up with sufficient treatment strategies - especially when facing a possible second surge in the covid-19 spread. moreover, it is to the best of our knowledge unknown whether a possible cns covid-19 infection will worsen existing psychopathology among patients with severe schizophrenia, schizoaffective- or bipolar affective disorder. the study is exploratory in nature including as many patients as possible for testing. the target population is patients diagnosed with schizophrenia, schizoaffective disorder or a bipolar affective disorder receiving in-patient or out-patient care via one of the psychiatric centres in the mental health services in the capital region of denmark. each patient will attend 3 study visits during a period of 12 months. a blood sample for igg and igm analysis for will be drawn at every visit.

Eligibility criteria:
inclusion criteria: 1. informed oral and written consent 2. age ≥ 18 years 3. patients with a diagnosis of schizophrenia, schizoaffective disorder or a bipolar affective disorder, according to the criteria of icd10 (international classification of diseases, world health organization (who)) 4. receiving psychiatric treatment from a hospital in- or outpatient-clinic in the catchment area of the capital region of denmark exclusion criteria: 1. patient with signs of infection should initially be transferred to the national test centres antigen-pcr testing. these patients will be offered to participate in next blood sampling interval.
high quality evidence of guangzhou lupus nephritis cohort (hope cohort)

Conditions: Lupus Nephritis (LN)

Summary: the goal of this observational study is to learn about the long-term renal and patient's survival of lupus nephritis (ln) patients in china. the main question it aims to answer is: does the renal and patient's survival improved in the long term period? participants who had renal biopsy proven lupus nephritis in one hospital will be followed up.

patients from 1996-2016 were retrospective enrolled and patients starting from 2017 were prespective enrolled

Eligibility criteria:
inclusion criteria: patients who had biopsy proven lupus nephritis in the first affiliated hospital of sun yat-sen university exclusion criteria: * less than 14 years old * refused to give written consent

Keywords: lupus lupus nephritis outcomes end stage kidney disease
efficacy and safety study in patients suffering from knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the primary objective of this study is to compare a combination of hyaluronic acid and chondroitin sulfate (v0220) to hyalgan® on pain relief in patients with symptomatic knee osteoarthritis (oa) over 24 weeks when administered in three weekly injections. chondroitin sulfate is one of the components of cartilage. studies have shown that chondroitin sulphate improves the quality of the hyaluronic acid produced in the joint. the benefit of v0220 combination is based on two main physicochemical properties, in line with the characteristics of osteoarthritic disease: optimising the rheological behaviour and improving the buffering effect on synovial flow ("outflow buffering").


Eligibility criteria:
inclusion criteria: * presenting with uni or bilateral medial and/or lateral femorotibial osteoarthritis of the knee evolving for more than 6 months * patients taking analgesic medications for at least 3 months prior to randomisation and dissatisfied with their current therapy exclusion criteria: * isolated symptomatic femoropatellar osteoarthritis * target knee prothesis * having undergone an articular lavage, or an arthroscopy or any surgery on the target knee in the 6 months preceding randomisation, * target knee osteoarthritis with clinical joint effusion at selection and at randomization * body mass index (bmi) greater than or equal to 30, * patient having received any corticosteroid treatment by any administration route (other than inhalers, ocular, auricular route) in the month preceding randomisation, * patient having received intra-articular steroid injection in the target knee within the month preceding randomisation or patient having received intra-articular hyaluronic acid in the target knee in the 6 months preceding randomisation
study to evaluate dnl201 in subjects with parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of dnl201 in subjects with parkinson's disease.


Eligibility criteria:
key inclusion criteria: * body mass index (bmi) between 18 and 35.0 kg/m2, inclusive * clinical diagnosis of parkinson's disease meeting uk brain bank criteria and h\&y stage i, ii, or iii. * spd subgroup without a lrrk2 mutation; pd lrrk2 subgroup with lrrk2 mutation * screening dopamine transporter (dat) spect scan with a dat deficit consistent with parkinson's disease * able to hold parkinson's disease medications 8 hours (overnight) prior to specific study assessments key exclusion criteria: * any history of clinically significant asthma, chronic obstructive pulmonary disease, or emphysema within 5 years of screening, or other clinically significant pulmonary disease within 6 months of screening * abnormal vitals including respiratory rate, body temperature, and blood pressure * pulmonary function tests (pfts) (fvc \<60% predicted, fev1 \<50% predicted, fev1:fvc ratio \<0.6, dlco \<70% predicted) * clinically significant neurologic disorder other than parkinson's disease, including history of stroke, cognitive impairment, seizure within 5 years of screening, or head trauma with loss of consciousness within 6 months of screening * montreal cognitive assessment (moca) score of \<24 at screening

Keywords: lrrk2 parkinson's disease movement disorders
effects of protein on muscle, gut microbiota and clinical outcome in patients with lung cancer-related sarcopenia

Conditions: Lung Cancer; Sarcopenia

Summary: sarcopenia is common in lung cancer patients. it is one of the significant factors affecting the overall survival, radiotherapy and chemotherapy efficacy, and quality of life of patients with lung cancer. previous studies have shown that increased protein intake can stimulate postprandial muscle synthesis, and improve muscle mass, strength, function, and overall survival. however, most previous studies have focused on the intervention of whey protein, while the protective effect of soybean protein on lung cancer-related sarcopenia (lcrs) has not yet been fully explored and reached an agreement. so, this study aims to explore the effects of soy and whey protein on muscle, gut microbiota, and clinical outcomes among patients with lung cancer-related sarcopenia, to provide a reference for further nutrition treatment.

this study will last 6 months. for the duration of the study, an anticipated total of 90 participants will be randomly assigned to receive either a 30-gram protein supplement or a placebo daily. there will be a total of 5 study visits, and dietary records, questionnaires, blood and stool collection, and functional testing will occur at all study visits. intention-to-treat analysis (itt) and per-protocol analysis (pp) will be conducted in statistical analysis.

Eligibility criteria:
inclusion criteria: * age\>=18years old * patients with lung cancer and sarcopenia * ecog\<=2 * patients are able to provide written informed consent. exclusion criteria: * people who are allergic to soy protein and whey protein. * participants received any drugs or supplements known to influence effcet size, such as protein powder, anabolic steroids, or glucorticosteroid before the 3 months preceding the study. * participants with gastrointestinal bleeding, enterotomy or gastric bypass surgery before the 3 months preceding the study. * concurrent severe cardiac disease, liver and renal failure, which may significantly interfere with study compliance. * participants with electronic or mental device.

Keywords: soy protein whey protein lung cancer related sarcopenia
atrial fibrillation force contact ablation study

Conditions: Paroxysmal Atrial Fibrillation

Summary: this study will be divided into two phases. the purpose of the phase i registry is to assess the current force being used for ablation of symptomatic paroxysmal af in a wide range of operators in different canadian centres with the operators being blinded to the contact force data. in phase ii of the study, operators will have open use of the force contact data. phase i and ii data will be compared in order to assess the efficiency of using the thermocool® smarttouch™ catheter.

atrial fibrillation (af) is the most common arrhythmia affecting over 5% of the population above the age of 65 years. the use of percutaneous catheter ablation for symptomatic management has increased over the last decade. it is well established that af ablation is superior to anti-arrhythmic drugs for symptomatic recurrence of af. despite this, success rates with a single procedure for paroxysmal af is approximately 80% with the majority of recurrence due to recovery of lesions or "gaps" found at repeat procedures. in this study, patients with symptomatic paroxysmal atrial fibrillation (af) will undergo ablation using a newly health canada approved catheter with smarttouch technology that enables the measurement of catheter tip contact force and direction inside the heart. the purpose of phase i of the study is to assess the current force being used for ablation of symptomatic paroxysmal af in a wide range of operators in different canadian centres with the operators being blinded to the contact force data. the secondary objective will be to assess whether lesion recovery, as assessed in redo procedures, corresponds to contact force measurements. it is hypothesized that gaps found on repeat procedures will correspond to ablation lesions associated with a lower contact force. in phase ii, operators will have open use of the force contact data. phase i and ii data will be compared in order to assess the efficiency of using the smarttouch catheter. it is hypothesized that the open use of contact force data will decrease the procedural time and number of lesions to achieve bidirectional pulmonary vein isolation.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or greater. * patients undergoing first-time pulmonary vein catheter ablation for af. * patients with paroxysmal af. paroxysmal af will be defined as symptomatic episodes of af lasting less than 7 days or treated with cardioversion(s) within 48 hours of onset. * at least one episode of af must have been documented on telemetry, ambulatory monitor, or 12-lead ecg. * patients must be able and willing to provide written informed consent to participate in the clinical study. exclusion criteria: * patients with a history of any previous ablation for atrial fibrillation. * patients with a previous atriotomy scar, ie. mitral or tricuspid valve replacement or repair, asd surgery, cardiac transplant. * patients with an intracardiac thrombus * patients who are or may potentially be pregnant.

Keywords: atrial fibrillation catheter ablation electrophysiology cardiac arrhythmias
a comparison of zidovudine (azt) and stavudine in hiv-infected patients

Conditions: HIV Infections

Summary: to compare stavudine (d4t) and zidovudine (azt) in slowing the progression of hiv disease. to compare the antiviral activity of d4t versus azt as measured by plasma levels of p24 antigen and hiv viremia, and their relative efficacy by improvement and/or absence of adverse changes over time in laboratory parameters associated with hiv infection. to compare the safety of oral doses of d4t to azt in patients with hiv infection.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * azt. patients must have: * documented hiv infection as determined by a positive elisa and/or western blot. * absolute cd4 count of 100 - 500 cells/mm3 within 90 days prior to registration or a cd4 count of 50 - 99 cells/mm3 within 30 days prior to registration. * prior zidovudine therapy for at least 6 months and currently tolerating at least 500 mg daily. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * newly diagnosed aids-defining opportunistic infection requiring acute therapy at time of enrollment. * need for chronic systemic therapy at time of enrollment. * intractable diarrhea. * signs or symptoms of bilateral peripheral neuropathy at time of screening. * demonstrated intolerance to zidovudine therapy. * any other clinical conditions that would render the patient unsuitable for study or unable to comply with the dosing requirements. concurrent medication: excluded: * chronic systemic therapy with agents likely to suppress bone marrow, cause neurotoxicity, or create hepatic dysfunction. patients with the following prior conditions are excluded: * prior history of bilateral peripheral neuropathy. * demonstrated intolerance to zidovudine therapy. prior medication: excluded: * prior d4t, ddi, or ddc. * other investigational antiretroviral drugs (e.g., azddu, al 721, interferon, or immunomodulating drugs within 1 month prior to study entry or ribavirin within 3 months prior to study entry). * prior myelosuppressive, neurotoxic, or cytotoxic anticancer therapy within 3 months prior to study entry. * any prior therapy that would render the patient unsuitable for study or unable to comply with dosing requirements. required: * at least 6 months of prior azt and currently tolerating at least 500 mg daily, with the last dose received no more than 7 days prior to study entry.

Keywords: zidovudine stavudine
follow-up of psychological and neurocognitive gulf war outcome: relation to stress

Conditions: Gulf War Syndrome

Summary: this is the follow-up to an observational epidemiological study of psychological and neuropsychological outcomes of deployed and non-deployed gulf war-era veterans.

approximately 800 deployed and 250 nondeployed veterans were originally administered psychological assessment instruments shortly after the cessation of the gulf war. these veterans are currently being followed to evaluate longer-term psychological outcomes in relation to war-zone stress, intervening life stress, and individual difference factors and personal resources, such as coping and social support. approximately 75 of these veterans, oversampled for post-traumatic stress disorder, were administered a specialized neuropsychological battery emphasizing attention and memory. this sample will also be followed to evaluate longitudinal neuropsychological outcome in relation to ptsd status. a cross-sectional study will also be conducted examining visual, hierarchical attention in relation to ptsd diagnosis.

Eligibility criteria:
participation in time 1 data collection
singulair (r) as complementary therapy to fixed association regimen (0476-363)

Conditions: Asthma

Summary: the purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of asthma control questionnaire(acq), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.


Eligibility criteria:
inclusion criteria: * patient is currently a nonsmoker and has been a nonsmoker for at least 1 year * patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis exclusion criteria: * patient has been treated in an emergency room for asthma within 4 weeks or has been hospitalized for asthma within 3 months prior to visit 1 * patient with severe asthma, upper respiratory infection, sinusitis, infectious rhinitis, non-allergic rhinitis * patient has any active, acute, or chronic pulmonary disorder that is documented by history, physical examination